No profile data available.
Alaunos Therapeutics, Inc. (TCRT) is a healthcare company in the blood cancer treatment drugs industry, based in Fort Lauderdale, United States, with about 1 full-time employees.
It reported revenue of $5,000 for fiscal year 2025, down 50.0% from fiscal year 2024, and net income of -$4.18 million. Its market capitalization was $2.30 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs.
Alaunos Therapeutics reported $5,000 in revenue for fiscal year 2025, down 50.0% from $10,000 in fiscal year 2024.
$2.30 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include Cellectar Biosciences, Inc. (CLRB), IN8bio, Inc. (INAB), Aptevo Therapeutics Inc. (APVO), CERo Therapeutics Holdings, Inc. (CERO).